Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

iMDx Welcomes New Diagnostics Sales Leader to Prepare for Planned GraftAssureDx Launch

14 October 2026 · By · Wire by Fusion42

Published

14 October 2026

Topic

operational-macro

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at stocktitan.net →

◆ Verified

Fusion42 · 14 October 2026 · Fusion42 review

Insight Molecular Diagnostics (iMDx) appointed Donnie Purto as Senior Vice President of Sales to lead commercialization efforts ahead of its planned GraftAssureDx launch, which remains pending FDA authorization.

This Wire brief sits within Fusion42's coverage of Medtech, and 2 sources have reported it.

◆ ◆ The Wire takeaway

You need to prepare for a changing regulatory hurdle as GraftAssureDx awaits FDA approval before launch. Sales and commercial leaders will become key contacts this year to access the upcoming transplant diagnostics market.

◆ Coverage

2 sources · 14 Oct 2026

◆ Related on Wire

◆ Topics

Medtechfda-approvaldiagnosticscommercial-launchorgan-transplantleadership-change